CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -486.08% | -486.08% | 14.88% | 14.88% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -486.08% | -486.08% | 14.88% | 14.88% | -- |
| Operating Income | 486.08% | 486.08% | -14.88% | -14.88% | -- |
| Income Before Tax | 320.99% | 320.99% | -14.88% | -14.88% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 320.99% | 320.99% | -14.88% | -14.88% | -- |
| Earnings from Discontinued Operations | -1,298.25% | -1,298.25% | -2,961.60% | -2,961.60% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.26% | 60.26% | -372.83% | -372.83% | -- |
| EBIT | 486.08% | 486.08% | -14.88% | -14.88% | -- |
| EBITDA | -- | -- | -- | 91.44% | -- |
| EPS Basic | 60.33% | 60.26% | -372.22% | -372.22% | -545.26% |
| Normalized Basic EPS | 485.79% | 487.91% | -14.77% | -14.77% | -- |
| EPS Diluted | 60.33% | 60.26% | -372.22% | -372.22% | -545.26% |
| Normalized Diluted EPS | 485.79% | 487.91% | -14.77% | -14.77% | -- |
| Average Basic Shares Outstanding | 0.09% | 0.09% | 0.09% | 0.09% | 0.94% |
| Average Diluted Shares Outstanding | 0.09% | 0.09% | 0.09% | 0.09% | 0.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
